LV12342B - PROGESTERON FOR REDUCTION OR REDUCTION OF EXTRACTION - Google Patents

PROGESTERON FOR REDUCTION OR REDUCTION OF EXTRACTION Download PDF

Info

Publication number: LV12342B
Authority: LV; Latvia
Prior art keywords: ischemia; progesterone; pharmaceutical preparation; myocardial ischemia; preparation according
Prior art date: 1996-11-04

Application number

LVP-99-88A

Other languages

English (en)

Latvian (lv)

Other versions

LV12342A (lv

Inventor

Howard L. Levine

William J. Bologna

Original Assignee

Columbia Laboratories (Bermuda) Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-04

Filing date

1999-05-28

Publication date

2000-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24987712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12342(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-05-28 Application filed by Columbia Laboratories (Bermuda) Limited filed Critical Columbia Laboratories (Bermuda) Limited

1999-09-20 Publication of LV12342A publication Critical patent/LV12342A/xx

2000-01-20 Publication of LV12342B publication Critical patent/LV12342B/en

Links

RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 96
239000000186 progesterone Substances 0.000 title claims abstract description 45
229960003387 progesterone Drugs 0.000 title claims abstract description 45
208000028867 ischemia Diseases 0.000 title claims abstract description 34
208000031225 myocardial ischemia Diseases 0.000 claims abstract description 29
229940011871 estrogen Drugs 0.000 claims abstract description 28
239000000262 estrogen Substances 0.000 claims abstract description 28
238000002560 therapeutic procedure Methods 0.000 claims abstract description 19
230000009286 beneficial effect Effects 0.000 claims abstract description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 32
229920000642 polymer Polymers 0.000 claims description 27
238000011282 treatment Methods 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 18
208000029078 coronary artery disease Diseases 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
230000009245 menopause Effects 0.000 claims description 5
208000024172 Cardiovascular disease Diseases 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
239000000583 progesterone congener Substances 0.000 abstract description 21
230000007211 cardiovascular event Effects 0.000 abstract description 7
230000007423 decrease Effects 0.000 abstract description 5
239000013589 supplement Substances 0.000 abstract description 3
238000000034 method Methods 0.000 abstract description 2
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 24
229960002985 medroxyprogesterone acetate Drugs 0.000 description 24
239000000203 mixture Substances 0.000 description 17
238000009472 formulation Methods 0.000 description 13
230000000694 effects Effects 0.000 description 10
238000009164 estrogen replacement therapy Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
229920002125 Sokalan® Polymers 0.000 description 6
229920000148 Polycarbophil calcium Polymers 0.000 description 5
230000035587 bioadhesion Effects 0.000 description 5
239000000227 bioadhesive Substances 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
229950005134 polycarbophil Drugs 0.000 description 5
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
235000019482 Palm oil Nutrition 0.000 description 4
229960001631 carbomer Drugs 0.000 description 4
230000008859 change Effects 0.000 description 4
238000004132 cross linking Methods 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000002540 palm oil Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 3
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
125000005456 glyceride group Chemical group 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
239000003906 humectant Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
235000010199 sorbic acid Nutrition 0.000 description 3
239000004334 sorbic acid Substances 0.000 description 3
229940075582 sorbic acid Drugs 0.000 description 3
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000005800 cardiovascular problem Effects 0.000 description 2
229940000593 crinone Drugs 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
229940083544 estradiol 2 mg Drugs 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 2
238000002657 hormone replacement therapy Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000004584 polyacrylic acid Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000004904 shortening Methods 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000002253 anti-ischaemic effect Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000008061 calcium-channel-blocking effect Effects 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
229940085237 carbomer-980 Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000004040 coloring Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
229940083543 estradiol 1 mg Drugs 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
229940059904 light mineral oil Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
229940018198 medroxyprogesterone acetate 5 mg Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000000178 monomer Substances 0.000 description 1
BLYOHBPLFYXHQA-UHFFFAOYSA-N n,n-bis(prop-2-enyl)prop-2-enamide Chemical compound C=CCN(CC=C)C(=O)C=C BLYOHBPLFYXHQA-UHFFFAOYSA-N 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
-1 plasticizing aģents Substances 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000009862 primary prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
150000003839 salts Chemical group 0.000 description 1
230000009863 secondary prevention Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
230000000283 vasomotion Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Vascular Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LVP-99-88A 1996-11-04 1999-05-28 PROGESTERON FOR REDUCTION OR REDUCTION OF EXTRACTION LV12342B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/743,153 US5985861A (en)	1996-11-04	1996-11-04	Progesterone for treating or reducing ischemia
PCT/US1997/020923 WO1998019681A1 (fr)	1996-11-04	1997-11-04	Progesterone utilisee pour traiter ou reduire l'ischemie

Publications (2)

Publication Number	Publication Date
LV12342A LV12342A (lv)	1999-09-20
LV12342B true LV12342B (en)	2000-01-20

Family

ID=24987712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-99-88A LV12342B (en)	1996-11-04	1999-05-28	PROGESTERON FOR REDUCTION OR REDUCTION OF EXTRACTION

Country Status (26)

Country	Link
US (2)	US5985861A (fr)
EP (1)	EP0956023B1 (fr)
KR (1)	KR100434623B1 (fr)
CN (1)	CN100341512C (fr)
AR (1)	AR009407A1 (fr)
AT (1)	ATE321558T1 (fr)
AU (1)	AU715740C (fr)
BR (1)	BR9710918A (fr)
CA (1)	CA2270565C (fr)
DE (1)	DE69735598T2 (fr)
DK (1)	DK0956023T3 (fr)
ES (1)	ES2262196T3 (fr)
GE (1)	GEP20022630B (fr)
HU (1)	HUP9904045A3 (fr)
IL (1)	IL127455A (fr)
LV (1)	LV12342B (fr)
MA (1)	MA24391A1 (fr)
MY (1)	MY121627A (fr)
NO (1)	NO324278B1 (fr)
NZ (1)	NZ335306A (fr)
PE (1)	PE9899A1 (fr)
PT (1)	PT956023E (fr)
RO (1)	RO120607B1 (fr)
UA (1)	UA66772C2 (fr)
WO (1)	WO1998019681A1 (fr)
ZA (1)	ZA979862B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6056972A (en) *	1997-02-26	2000-05-02	Dimera, Llc	Method for reducing coronary artery reactivity
US6602487B1 (en)	1997-02-26	2003-08-05	Dimera Incorporated	Methods and tests for producing and for inhibiting coronary artery vasospasms
DE69819748T2 (de)	1997-09-12	2004-09-30	Columbia Laboratories (Bermuda) Ltd.	Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US20040234606A1 (en) *	1997-09-12	2004-11-25	Levine Howard L.	Localized vaginal delivery without detrimental blood levels
GB0107383D0 (en) *	2001-03-23	2001-05-16	Univ Edinburgh	Lipid profile modulation
US20080182841A1 (en) *	2001-10-29	2008-07-31	Levine Howard L	Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20030114394A1 (en) *	2001-10-29	2003-06-19	Levine Howard L.	Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US8425892B2 (en)	2001-10-29	2013-04-23	Columbia Laboratories, Inc.	Extended, controlled-release pharmaceutical compositions using charged polymers
US7572780B2 (en) *	2003-01-21	2009-08-11	Dimera, Incorporated	Method and kit for reducing the symptoms of peripheral vascular disease
DE602004026173D1 (de) *	2003-04-29	2010-05-06	Gen Hospital Corp	Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
DE102005027004B4 (de) *	2005-06-10	2020-03-19	Continental Automotive Gmbh	Scheibenwaschvorrichtung
US8828981B2 (en)	2007-02-06	2014-09-09	George Creasy	Progesterone for the treatment or prevention of spontaneous preterm birth
PL2359807T3 (pl)	2008-02-04	2017-12-29	Ferring B.V.	Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (fr)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Formulations d'hormones substitutives combinées naturelles et traitement hormonal substitutif
RU2016141135A (ru)	2014-07-29	2018-08-28	Терапьютиксмд, Инк.	Трансдермальный крем
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173071A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Composition pharmaceutique d'hormone stéroïde
WO2017173044A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
US11512107B2 (en)	2018-09-07	2022-11-29	Trustees Of Dartmouth College	Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation
US11787835B2 (en)	2018-09-07	2023-10-17	Trustees Of Dartmouth College	C19 scaffolds and steroids and methods of use and manufacture thereof
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
GB202316026D0 (en) *	2023-10-19	2023-12-06	Theramex Hq Uk Ltd	Methods of prevention or treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1124906A1 (ru) *	1982-05-25	1984-11-23	Ивановский государственный медицинский институт им.А.С.Бубнова	Способ коррекции ишемических повреждений консервированной донорской почки
EP0163696B1 (fr) *	1983-11-14	1992-11-25	Columbia Laboratories, Inc.	Application d'une bioadhesive
US5543150A (en) *	1993-09-15	1996-08-06	Columbia Laboratories, Inc.	Method of progesterone delivery and affect thereof

1996
- 1996-11-04 US US08/743,153 patent/US5985861A/en not_active Expired - Lifetime
1997
- 1997-11-03 ZA ZA9709862A patent/ZA979862B/xx unknown
- 1997-11-03 MA MA24853A patent/MA24391A1/fr unknown
- 1997-11-04 CA CA002270565A patent/CA2270565C/fr not_active Expired - Fee Related
- 1997-11-04 MY MYPI97005220A patent/MY121627A/en unknown
- 1997-11-04 ES ES97946681T patent/ES2262196T3/es not_active Expired - Lifetime
- 1997-11-04 WO PCT/US1997/020923 patent/WO1998019681A1/fr not_active Ceased
- 1997-11-04 DE DE69735598T patent/DE69735598T2/de not_active Expired - Fee Related
- 1997-11-04 AU AU51801/98A patent/AU715740C/en not_active Ceased
- 1997-11-04 AT AT97946681T patent/ATE321558T1/de not_active IP Right Cessation
- 1997-11-04 KR KR10-1999-7003965A patent/KR100434623B1/ko not_active Expired - Fee Related
- 1997-11-04 AR ARP970105144A patent/AR009407A1/es unknown
- 1997-11-04 CN CNB971994145A patent/CN100341512C/zh not_active Expired - Fee Related
- 1997-11-04 GE GEAP19974830A patent/GEP20022630B/en unknown
- 1997-11-04 UA UA99052985A patent/UA66772C2/uk unknown
- 1997-11-04 DK DK97946681T patent/DK0956023T3/da active
- 1997-11-04 EP EP97946681A patent/EP0956023B1/fr not_active Expired - Lifetime
- 1997-11-04 PE PE1997000985A patent/PE9899A1/es not_active Application Discontinuation
- 1997-11-04 PT PT97946681T patent/PT956023E/pt unknown
- 1997-11-04 HU HU9904045A patent/HUP9904045A3/hu unknown
- 1997-11-04 BR BR9710918-5A patent/BR9710918A/pt not_active Application Discontinuation
- 1997-11-04 NZ NZ335306A patent/NZ335306A/xx not_active IP Right Cessation
- 1997-11-04 RO RO99-00508A patent/RO120607B1/ro unknown
1998
- 1998-12-09 IL IL12745598A patent/IL127455A/xx not_active IP Right Cessation
1999
- 1999-02-01 US US09/240,610 patent/US6054447A/en not_active Expired - Lifetime
- 1999-05-03 NO NO19992140A patent/NO324278B1/no unknown
- 1999-05-28 LV LVP-99-88A patent/LV12342B/en unknown

Also Published As

Publication number	Publication date
CA2270565A1 (fr)	1998-05-14
NO992140D0 (no)	1999-05-03
ATE321558T1 (de)	2006-04-15
RO120607B1 (ro)	2006-05-30
BR9710918A (pt)	2000-01-11
KR20000053056A (ko)	2000-08-25
MY121627A (en)	2006-02-28
PT956023E (pt)	2006-08-31
IL127455A0 (en)	1999-10-28
DK0956023T3 (da)	2006-08-07
CN1235549A (zh)	1999-11-17
HUP9904045A2 (hu)	2000-04-28
ES2262196T3 (es)	2006-11-16
NO324278B1 (no)	2007-09-17
AU715740C (en)	2004-04-29
NO992140L (no)	1999-05-04
AU5180198A (en)	1998-05-29
HK1020534A1 (en)	2000-05-12
AU715740B2 (en)	2000-02-10
DE69735598T2 (de)	2006-12-28
DE69735598D1 (de)	2006-05-18
US6054447A (en)	2000-04-25
WO1998019681A1 (fr)	1998-05-14
CA2270565C (fr)	2007-02-20
US5985861A (en)	1999-11-16
GEP20022630B (en)	2002-02-25
PE9899A1 (es)	1999-02-08
KR100434623B1 (ko)	2004-06-05
EP0956023B1 (fr)	2006-03-29
EP0956023A1 (fr)	1999-11-17
UA66772C2 (uk)	2004-06-15
LV12342A (lv)	1999-09-20
IL127455A (en)	2005-03-20
HUP9904045A3 (en)	2000-11-28
MA24391A1 (fr)	1998-07-01
ZA979862B (en)	1998-05-25
CN100341512C (zh)	2007-10-10
NZ335306A (en)	2000-12-22
AR009407A1 (es)	2000-04-12

Publication	Publication Date	Title
US5985861A (en)	1999-11-16	Progesterone for treating or reducing ischemia
JP3211892B2 (ja)	2001-09-25	肛門疾患を治療する窒素酸化物供与体及び方法
Nilsson et al.	1971	Treatment of menorrhagia
US6306914B1 (en)	2001-10-23	Progestin therapy for maintaining amenorrhea
US20040110732A1 (en)	2004-06-10	Pharmaceutical composition for transdermal or transmucosal administration comprising at least one progestin and/or at least one oestrogen, process for preparing it and uses thereof
US6831073B1 (en)	2004-12-14	Hormonal composition consisting of an oestrogen compound and of a progestational compound
WO2000037071A1 (fr)	2000-06-29	Traitement local de dermatoses
Zoma et al.	2004	Effects of combined use of sildenafil citrate (Viagra) and 17β-estradiol on ovine coronary and uterine hemodynamics
KR100450649B1 (ko)	2004-11-16	호르몬약물및에스트로겐결핍을치유하기위한그의용도
JPS6227A (ja)	1987-01-06	皮膚科ならびに眼科用の外傷、潰瘍治療用クリーム剤
DE60036723T2 (de)	2008-07-17	Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
HK1020534B (en)	2006-06-02	Use of progesterone for treating or reducing ischemia in menopausal women receiving estrogen
MXPA99004130A (es)	2000-05-01	Progesterona para el tratamiento o la reduccion de isquemia
JP2002503215A (ja)	2002-01-29	虚血を治療又は抑制するためのプロゲステロン
UA79421C2 (en)	2007-06-25	Progestin therapy with regular menstrual bleeding
HK1121685A (en)	2009-04-30	Hormonal composition consisting of an estrogen compound and of a progestational compound